Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

Powles T., Csőszi T., Özgüroğlu M., Matsubara N., Géczi L., Cheng S. Y., ...Daha Fazla

The Lancet. Oncology, cilt.22, ss.931-945, 2021 (SCI-Expanded, Scopus) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/s1470-2045(21)00152-2
  • Dergi Adı: The Lancet. Oncology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.931-945
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background PD-1 and PD-L1 inhibitors are active in metastatic urothelial carcinoma, but positive randomised data supporting their use as a first-line treatment are lacking. In this study we assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemotherapy for patients with previously untreated advanced urothelial carcinoma.